［1］ LOUIS DN,PERRY A,WESSELING P,et al.The 2021 WHO classification of tumors of the central nervous system:a summary［J］.Neuro-Oncology,2021,23(8):1231-1251.
［2］ YAN H,PARSONS DW,JIN G,et al.IDH1 and IDH2 mutations in gliomas［J］.The New England Journal of Medicine,2009,360(8):765-773.
［3］ BEIKO J,SUKI D,HESS KR,et al.IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection［J］.Neuro-Oncology,2014,16(1):81-91.
［4］ KILLELA PJ,PIROZZI CJ,HEALY P,et al.Mutations in IDH1,IDH2,and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas［J］.Oncotarget,2014,5(6):1515-1525.
［5］ HUANG J,YU J,TU L,et al.Isocitrate dehydrogenase mutations in glioma:from basic discovery to therapeutics development［J］.Frontiers in Oncology,2019,9:506.
［6］ DANG L,WHITE DW,GROSS S,et al.Cancer-associated IDH1 mutations produce 2-hydroxyglutarate［J］.Nature,2009,462(7274):739.
［7］ CHOI C,RAISANEN JM,GANJI SK,et al.Prospective longitudinal analysis of 2-hydroxyglutarate magnetic resonance spectroscopy identifies broad clinical utility for the management of patients with IDH-mutant glioma［M］.United States:American Society of Clinical Oncology,2016:4030-4039.
［8］ POPE WB,PRINS RM,ALBERT THOMAS M,et al.Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy［J］.Journal of Neuro-Oncology,2012,107(1):197-205.
［9］ SUH CH,KIM HS,JUNG SC,et al.2-hydroxyglutarate MR spectroscopy for prediction of isocitrate dehydrogenase mutant glioma:a systemic review and meta-analysis using individual patient data［J］.Neuro-Oncology,2018,20(12):1573-1583.
［10］ BRANZOLI F,DI STEFANO AL,CAPELLE L,et al.Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy［J］.Neuro-Oncology,2018,20(7):907-916.
［11］ IWAHASHI H,NAGASHIMA H,TANAKA K,et al.2-hydroxyglutarate magnetic resonance spectroscopy in adult brainstem glioma［J］.Journal of Neurosurgery,2023,139(2):355-362.
［12］ JUSKANIC D,MISTINOVA JP,HOLLY S,et al.Diagnostic performance of edited 2HG MR spectroscopy of central glioma in the clinical environment［J］.Magma (New York,N.Y.),2022,35(1):45-52.
［13］ NGUYEN TB,MELKUS G,TACCONE M,et al.Preoperative determination of isocitrate dehydrogenase mutation in gliomas using spectral editing MRS?:A prospective study［J］.Journal of Magnetic Resonance Imaging,2021,53(2):416-426.
［14］ SUH CH,KIM HS,PARK JE,et al.Comparative value of 2-hydroxyglutarate-to-lipid and lactate ratio versus 2-hydroxyglutarate concentration on MR spectroscopic images for predicting isocitrate dehydrogenase mutation status in gliomas［J］.Radiology Imaging Cancer,2020,2(4):e190083.
［15］ EMIR UE,LARKIN SJ,DE PENNINGTON N,et al.Noninvasive quantification of 2-hydroxyglutarate in human gliomas with IDH1 and IDH2 mutations［J］.Cancer Research,2016,76(1):43-49.
［16］ SHEN X,VOETS NL,LARKIN SJ,et al.A noninvasive comparison study between human gliomas with IDH1 and IDH2 mutations by MR spectroscopy［J］.Metabolites,2019,9(2):35.
［17］ GORYAWALA M,SARAF-LAVI E,NAGORNAYA N,et al.The association between whole-brain MR spectroscopy and IDH mutation status in gliomas［J］.Journal of Neuroimaging:Official Journal of the American Society of Neuroimaging,2020,30(1):58-64.
［18］ BISDAS S,CHADZYNSKI GL,BRAUN C,et al.MR spectroscopy for in vivo assessment of the oncometabolite 2-hydroxyglutarate and its effects on cellular metabolism in human brain gliomas at 9.4T［J］.Journal of Magnetic Resonance Imaging:JMRI,2016,44(4):823-833.
［19］ NAGASHIMA H,TANAKA K,SASAYAMA T,et al.Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma［J］.Neuro-Oncology,2016,18(11):1559-1568.
［20］ LI X,STRASSER B,JAFARI-KHOUZANI K,et al.Super-resolution whole-brain 3D MR spectroscopic imaging for mapping D-2-hydroxyglutarate and tumor metabolism in isocitrate dehydrogenase 1-mutated human gliomas［J］.Radiology,2020,294(3):589-597.
［21］ BRANZOLI F,PONTOIZEAU C,TCHARA L,et al.Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy［J］.Neuro-Oncology,2019,21(6):765-774.
［22］ BRANZOLI F,DEELCHAND DK,SANSON M,et al.In vivo 1H MRS detection of cystathionine in human brain tumors［J］.Magnetic Resonance in Medicine,2019,82(4):1259-1265.
［23］ BRANZOLI F,DEELCHAND DK,LISERRE R,et al.The influence of cystathionine on neurochemical quantification in brain tumor in vivo MR spectroscopy［J］.Magnetic Resonance in Medicine,2022,88(2):537-545.
［24］ OSTROM QT,GITTLEMAN H,FARAH P,et al.CBTRUS statistical report:Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010［J］.Neuro-Oncology,2013,15 Suppl 2(Suppl 2):ii1-56.
［25］ SHAKIR TM,FENGLI L,CHENGUANG G,et al.1H-MR spectroscopy in grading of cerebral glioma:A new view point,MRS image quality assessment［J］.Acta Radiologica Open,2022,11(2):205846012210770.
［26］ GAO W,WANG X,LI F,et al.Cho/Cr ratio at MR spectroscopy as a biomarker for cellular proliferation activity and prognosis in glioma:correlation with the expression of minichromosome maintenance protein 2［J］.Acta Radiologica,2019,60(1):106-112.
［27］ YAO R,CHENG A,LIU M,et al.The diagnostic value of apparent diffusion coefficient and proton magnetic resonance spectroscopy in the grading of pediatric gliomas［J］.Journal of Computer Assisted Tomography,2021,45(2):269-276.
［28］ LIN Q,TANG L,LIN Z.Application value of 3.0-T multivoxel 1H-MR spectroscopy in the peritumoral tissue of brain astrocytic tumors［J］.Neurology India,2020,68(2):389.
［29］ HU X,XUE M,SUN S,et al.Combined application of MRS and DWI can effectively predict cell proliferation and assess the grade of glioma:A prospective study［J］.Journal of Clinical Neuroscience:Official Journal of the Neurosurgical Society of Australasia,2021,83:56-63.
［30］ NAKAMURA H,DOI M,SUZUKI T,et al.The significance of lactate and lipid peaks for predicting primary neuroepithelial tumor grade with proton MR spectroscopy［J］.Magnetic Resonance in Medical Sciences,2018,17(3):238-243.
［31］ TAN AC,ASHLEY DM,LOPEZ GY,et al.Management of glioblastoma:State of the art and future directions［J］.CA:A Cancer Journal for Clinicians,2020,70(4):299-312.
［32］ LE FEVRE C,LHERMITTE B,AHLE G,et al.Pseudoprogression versus true progression in glioblastoma patients:A multiapproach literature review:Part 1-Molecular,morphological and clinical features［J］.Critical Reviews in Oncology/Hematology,2021,157:103188.
［33］ BRJ VAN D,PJ VAN L,GA H,et al.Diagnostic accuracy of magnetic resonance imaging techniques for treatment response evaluation in patients with high-grade glioma,a systematic review and meta-analysis［M］.Germany:Springer Berlin Heidelberg,2017:4129-4144.
［34］ HYGINO DA CRUZ LC,RODRIGUEZ I,DOMINGUES RC,et al.Pseudoprogression and pseudoresponse:imaging challenges in the assessment of posttreatment glioma［J］.AJNR.American Journal of Neuroradiology,2011,32(11):1978-1985.
［35］ CLUCERU J,NELSON SJ,WEN Q,et al.Recurrent tumor and treatment-induced effects have different MR signatures in contrast enhancing and non-enhancing lesions of high-grade gliomas［J］.Neuro-Oncology,2020,22(10):1516-1526.
［36］ VERMA G,CHAWLA S,MOHAN S,et al.Three-dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma［J］.NMR in Biomedicine,2019,32(2):e4042.
［37］ DI COSTANZO A,SCARABINO T,TROJSI F,et al.Recurrent glioblastoma multiforme versus radiation injury:a multiparametric 3-T MR approach［J］.La Radiologia Medica,2014,119(8):616-624.
［38］ MATSUSUE E,FINK JR,ROCKHILL JK,et al.Distinction between glioma progression and post-radiation change by combined physiologic MR imaging［J］.Neuroradiology,2010,52(4):297-306.
［39］ PARRY AH,WANI AH,SHAHEEN FA,et al.Evaluation of intracranial tuberculomas using diffusion-weighted imaging (DWI),magnetic resonance spectroscopy (MRS) and susceptibility weighted imaging (SWI)［J］.The British Journal of Radiology,2018,91(1091):20180342.
［40］ SERVER A,JOSEFSEN R,KULLE B,et al.Proton magnetic resonance spectroscopy in the distinction of high-grade cerebral gliomas from single metastatic brain tumors［J］.Acta Radiologica (Stockholm,Sweden:1987),2010,51(3):316-325.
［41］ WANG L,CHEN G,DAI K.Hydrogen proton magnetic resonance spectroscopy (MRS) in differential diagnosis of intracranial tumors:A systematic review［J］.Contrast Media & Molecular Imaging,2022,2022:1-8.
［42］ TSOUGOS I,SVOLOS P,KOUSI E,et al.Differentiation of glioblastoma multiforme from metastatic brain tumor using proton magnetic resonance spectroscopy,diffusion and perfusion metrics at 3 T［J］.Cancer Imaging:The Official Publication of the International Cancer Imaging Society,2012,12(3):423-436.
［43］ GROSSMAN R,RAM Z.Posterior fossa intra-axial tumors in adults［J］.World Neurosurgery,2016,88:140-145.
［44］ MORA P,PONS A,COS M,et al.Magnetic resonance spectroscopy in posterior fossa tumours:the tumour spectroscopic signature may improve discrimination in adults among haemangioblastoma,ependymal tumours,medulloblastoma,and metastasis［J］.European Radiology,2019,29(6):2792-2801.
［45］ MANIAS KA,HARRIS LM,DAVIES NP,et al.Prospective multicentre evaluation and refinement of an analysis tool for magnetic resonance spectroscopy of childhood cerebellar tumours［J］.Pediatric Radiology,2018,48(11):1630-1641.
［46］ DAVIES NP,ROSE HEL,MANIAS KA,et al.Added value of magnetic resonance spectroscopy for diagnosing childhood cerebellar tumours［M］.United States:Wiley,2022:e4630.
［47］ DAVIES NP,WILSON M,HARRIS LM,et al.Identification and characterisation of childhood cerebellar tumours by in vivo proton MRS［J］.NMR in Biomedicine,2008,21(8):908-918.